| Title | Cancer Biotherapy and Radiopharmaceuticals |
| Abbreviation | Cancer Biother. Radiopharm. |
| Publication Type | Journal |
| Subject Area, Categories, Scope | Medicine (miscellaneous) (Q2); Pharmacology (Q2); Radiology, Nuclear Medicine and Imaging (Q2); Cancer Research (Q3); Oncology (Q3) |
| h-index | 66 |
| Overall Rank/Ranking | 7817 |
| SCImago Journal Rank (SJR) | 0.650 |
| Impact Score | 3.72 |
| Publisher | Mary Ann Liebert Inc. |
| Country | United States |
| ISSN | 10849785, 15578852 |
| Best Quartile | Q2 |
| Coverage History | 1996-2022 |
Cancer Biotherapy and Radiopharmaceuticals is a peer-reviewed journal covering cutting-edge biotherapy and innovative investigations of methods to improve cancer therapy. Includes more selective delivery of drugs, biologicals, radiopharmaceuticals, or other agents, and advances in delivery instrumentation and technology, with the aim of increasing efficacy of therapy and/or decreasing toxicity or improving convenience of therapy.
Topics include:
Pre-targeted cancer therapy
Clinical trials in cancer research
Antibody therapy and imaging
Tumor cell vaccines
Radioimmunotherapy
T-cell therapy
Molecular targeted therapy and imaging
Drug resistance
Cancer Biotherapy and Radiopharmaceuticals is a journal covering the technologies/fields/categories related to Medicine (miscellaneous) (Q2); Pharmacology (Q2); Radiology, Nuclear Medicine and Imaging (Q2); Cancer Research (Q3); Oncology (Q3). It is published by Mary Ann Liebert Inc.. The overall rank of Cancer Biotherapy and Radiopharmaceuticals is 7817. According to SCImago Journal Rank (SJR), this journal is ranked 0.650. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come. SJR acts as an alternative to the Journal Impact Factor (or an average number of citations received in last 2 years). This journal has an h-index of 66. The best quartile for this journal is Q2.
The ISSN of Cancer Biotherapy and Radiopharmaceuticals journal is 10849785, 15578852. An International Standard Serial Number (ISSN) is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic. Cancer Biotherapy and Radiopharmaceuticals is cited by a total of 898 articles during the last 3 years (Preceding 2022).
The Impact IF 2022 of Cancer Biotherapy and Radiopharmaceuticals is 3.72, which is computed in 2023 as per its definition. Cancer Biotherapy and Radiopharmaceuticals IF is increased by a factor of 0.06 and approximate percentage change is 1.64% when compared to preceding year 2021, which shows a rising trend. The impact IF, also denoted as Journal impact score (JIS), of an academic journal is a measure of the yearly average number of citations to recent articles published in that journal. It is based on Scopus data.
Impact IF 2022 of Cancer Biotherapy and Radiopharmaceuticals is 3.72. If the same upward trend persists, Impact IF may rise in 2023 as well.
| Year | Impact IF |
|---|---|
| 2023/2024 | Coming Soon |
| 2022 | 3.72 |
| 2021 | 3.66 |
| 2020 | 2.48 |
| 2019 | 1.77 |
| 2018 | 1.73 |
| 2017 | 1.58 |
| 2016 | 1.71 |
| 2015 | 1.93 |
| 2014 | 2.04 |
Cancer Biotherapy and Radiopharmaceuticals has an h-index of 66. It means 66 articles of this journal have more than 66 number of citations. The h-index is a way of measuring the productivity and citation impact of the publications. The h-index is defined as the maximum value of h such that the given journal/author has published h papers that have each been cited at least h number of times.
The ISSN of Cancer Biotherapy and Radiopharmaceuticals is 10849785, 15578852. ISSN stands for International Standard Serial Number.
An ISSN is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic.
The overall rank of Cancer Biotherapy and Radiopharmaceuticals is 7817. According to SCImago Journal Rank (SJR), this journal is ranked 0.650. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come.
| Year | SJR |
|---|---|
| 2023/2024 | Coming Soon |
| 2022 | 0.650 |
| 2021 | 0.592 |
| 2020 | 0.716 |
| 2019 | 0.544 |
| 2018 | 0.545 |
| 2017 | 0.567 |
| 2016 | 0.694 |
| 2015 | 0.680 |
| 2014 | 0.638 |
| Year | Ranking |
|---|---|
| 2023/2024 | Coming Soon |
| 2022 | 7817 |
| 2021 | 8371 |
| 2020 | 6936 |
| 2019 | 9093 |
| 2018 | 8798 |
| 2017 | 8298 |
| 2016 | 6828 |
| 2015 | 6978 |
| 2014 | 7299 |
Cancer Biotherapy and Radiopharmaceuticals is published by Mary Ann Liebert Inc.. It's publishing house is located in United States. Coverage history of this journal is as following: 1996-2022. The organization or individual who handles the printing and distribution of printed or digital publications is known as Publisher.
Visit the official website of the journal/conference to check the further details about the call for papers.
The IS0 4 standard abbreviation of Cancer Biotherapy and Radiopharmaceuticals is Cancer Biother. Radiopharm.. This abbreviation ('Cancer Biother. Radiopharm.') is well recommended and approved for the purpose of indexing, abstraction, referencing and citing goals. It meets all the essential criteria of ISO 4 standard.
ISO 4 (International Organization for Standardization 4) is an international standard that defines a uniform and consistent system for abbreviating serial publication titles and journals.
If your research field is/are related to Medicine (miscellaneous) (Q2); Pharmacology (Q2); Radiology, Nuclear Medicine and Imaging (Q2); Cancer Research (Q3); Oncology (Q3), then please visit the official website of this journal.
The acceptance rate/percentage of any academic journal/conference depends upon many parameters. Some of the critical parameters are listed below.
It is essential to understand that the acceptance rate/rejection rate of papers varies among journals. Some Journals considers all the manuscripts submissions as a basis of acceptance rate computation. On the other hand, few consider the only manuscripts sent for peer review or few even not bother about the accurate maintenance of total submissions. Hence, it can provide a rough estimation only.
The best way to find out the acceptance rate is to reach out to the associated editor or to check the official website of the Journal/Conference.
Cancer Biotherapy and Radiopharmaceuticals latest impact IF is 3.72. It's evaluated in the year 2022. The highest and the lowest impact IF or impact score of this journal are 3.72 (2022) and 1.58 (2017), respectively, in the last 9 years. Moreover, its average IS is 2.29 in the previous 9 years.
The Cancer Biotherapy and Radiopharmaceuticals has an SJR (SCImago Journal Rank) of 0.650, according to the latest data. It is computed in the year 2023. In the past 9 years, this journal has recorded a range of SJR, with the highest being 0.716 in 2020 and the lowest being 0.544 in 2019. Furthermore, the average SJR of the Cancer Biotherapy and Radiopharmaceuticals over the previous 9-year period stands at 2.29.
The latest h-index of the Cancer Biotherapy and Radiopharmaceuticals is 66.
The Cancer Biotherapy and Radiopharmaceuticals is published by the Mary Ann Liebert Inc., with its country of publication being the United States.
The Cancer Biotherapy and Radiopharmaceuticals is currently ranked 7817 out of 27955 Journals, Conferences, and Book Series in the latest ranking. Over the course of the last 9 years, this journal has experienced varying rankings, reaching its highest position of 6828 in 2016 and its lowest position of 9093 in 2019.
The standard ISO4 abbreviation for the Cancer Biotherapy and Radiopharmaceuticals is Cancer Biother. Radiopharm..
Cancer Biotherapy and Radiopharmaceuticals is classified as a journal that the Mary Ann Liebert Inc. publishes.
The Cancer Biotherapy and Radiopharmaceuticals encompasses the following areas:
For a more comprehensive understanding of its scope, check the official website of this journal.
The Cancer Biotherapy and Radiopharmaceuticals is assigned the following International Standard Serial Numbers (ISSN): 10849785, 15578852.
The best quartile for the Cancer Biotherapy and Radiopharmaceuticals is Q2 (2022).
The Cancer Biotherapy and Radiopharmaceuticals coverage history can be summarized as follows: 1996-2022.
| Journal/Conference/Workshop/Book Title | Type | Ranking | Publisher | h-index | Impact Score |
|---|---|---|---|---|---|
| Business: Theory and Practice | journal | 13414 | Vilnius Gediminas Technical University | 21 | 2.47 |
| Journal of Competition Law and Economics | journal | 14815 | Oxford University Press | 29 | 0.72 |
| CESifo Economic Studies | journal | 14012 | Oxford University Press | 32 | 1.70 |
| Socialism and Democracy | journal | 26162 | Taylor and Francis Ltd. | 17 | 0.09 |
| Sex Education | journal | 5168 | Routledge | 41 | 2.82 |
| Palaeontographica Abteilung B: Palaeophytologie | book series | 15138 | E. Schweizerbart'sche Verlagsbuchhandlung | 16 | 2.20 |
| European Surgery - Acta Chirurgica Austriaca | journal | 16873 | Springer Medizin | 23 | 0.58 |
| Exploration Geophysics | journal | 16383 | Taylor and Francis Ltd. | 48 | 1.17 |
| Engenharia Agricola | journal | 15839 | Sociedade Brasileira de Engenharia Agricola | 30 | 1.12 |
| Expert Review of Clinical Pharmacology | journal | 5241 | Taylor and Francis Ltd. | 53 | 4.10 |
| Year | Impact Score (IS) |
|---|---|
| 2023/2024 | Coming Soon |
| 2022 | 3.72 |
| 2021 | 3.66 |
| 2020 | 2.48 |
| 2019 | 1.77 |
| 2018 | 1.73 |
| 2017 | 1.58 |
| 2016 | 1.71 |
| 2015 | 1.93 |
| 2014 | 2.04 |
